Canagliflozin antidiabetic drugs

Description Results NMA

CV events 0.86 [0.76; 0.98] Demonstrated

Hospitalization for heart failure 0.67 [0.52; 0.87]

Nephropathy 0.60 [0.47; 0.77]

amputation 1.97 [1.41; 2.75]

all causes death 0.87 [0.74; 1.02]

CVdeath 0.87 [0.72; 1.06]

fatal and non fatal stroke 0.87 [0.69; 1.09]

fatal and non fatal MI 0.89 [0.73; 1.09]

canagliflozin (n=5795)

vs.

placebo (n=4347)

double-blind

Sample size: 5795/4347

Primary endpoint: CV death, MI, stroke

FU duration: 188.2 weeks (mean)